AMG 386

Generic Name: AMG 386
Study IDStudied Indication or DiseasePhaseStudy TitleSynopsis
20050170Antiangiogenic therapy for advanced solid tumors.1bAn Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 with Motesanib, AMG 386 with Bevacizumab, AMG 386 with Sorafenib, and AMG 386 with Sunitinib in Adult Patients with Advanced Solid Tumors
20050191Advanced solid tumors1bA Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 with Chemotherapy in Adult Patients With Advanced Solid Tumors
20060159Metastatic clear cell carcinoma of the kidney2A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metastatic Clear Cell Carcinoma of the Kidney
20060212Advanced solid tumors1A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 386 in Adult Japanese Patients with Advanced Solid Tumors
20060341Metastatic or Locally Recurrent Breast Cancer2A Randomized, 4-Arm, Placebo-Controlled Phase 2 Trial of AMG 386 in Combination with Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects With Her2-Negative, Metastatic or Locally Recurrent Breast Cancer
20060439Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma2A Randomized, Double-blind, Multi-center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination with AMG 386 or Placebo in Subjects with Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
20060517Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancer3A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
20062042HER2-positive locally recurrent or metastatic breast cancer1bAn Open-Label Study of AMG 386 in Combination with Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects with HER2-positive Locally Recurrent or Metastatic Breast Cancer
20070182Advanced recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer1bA Phase 1b Study of AMG 386 in Combination with Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects with Advanced Recurrent Epithelial Ovarian Cancer
20070307Metastatic colorectal cancer2A Phase 2, Randomized, Double-Blind, Placebo Controlled Study of AMG 386 in Combination with FOLFIRI in Subjects with Previously Treated Metastatic Colorectal Carcinoma
20080579Metastatic renal cell carcinoma2Phase 2 Open-Label Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination with AMG 386 as First Line or Second Line Therapy for Subjects with Metastatic Renal Cell Carcinoma
20080580advanced or inoperable hepatocellular carcinoma2Phase 2, Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
20090155First-line treatment for high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancers1bA Phase 1b Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
20090277Advanced Solid Tumors1An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects with Normal and Impaired Renal Function
20090508Recurrent partially platinum sensitive or resistant epithelial ovarian, primary peritoneal or fallopian tube cancers3A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
20101151Advanced Solid Tumors1bAn Open-Label, Pharmacokinetic Drug-Drug Interaction (DDI) Study of AMG 386 in Combination with Paclitaxel in Adult Subjects with Advanced Solid Tumors